|
Demographic
| | | |
|
Age (years)
|
215
|
57.4 (49.1–64.7)
| |
|
Female
|
215
|
170 (79.0%)
| |
|
Menopause
|
170
|
111 (65.3%)
| |
|
Body mass index (kg/m2)
|
215
|
23.9 (21.3–26.2)
|
24.0 (21.5–26.2)
|
|
Smoker
|
210
|
65 (31.0%)
|
67 (31.9%)
|
|
Disease
| | | |
|
Disease duration (years)
|
215
|
9 (4–16)
| |
|
Age at disease onset (years)
|
215
|
45.0 (33.0–53.0)
| |
|
Rheumatoid factor-positive
|
202
|
97 (48.0%)
| |
|
Physician's global assessment score (visual analogue scale, 0–100 mm)
|
203
|
19.0 (8.0–39.8)
|
17.6 (8.5–30.0)
|
|
Modified Health Assessment Questionnaire (range 1–4)
|
214
|
1.50 (1.13–1.75)
|
1.50 (1.13–1.87)
|
|
Erythrocyte sedimentation rate (mm/hour)
|
210
|
16 (9–27)
|
14 (8–27)
|
|
Disease activity score including 28 joints
|
202
|
4.04 (3.17–4.96)
|
4.26 (3.36–5.06)
|
|
Medication
| | | |
|
Ever user of disease-modifying antirheumatic drugs
|
213
|
177 (83.1%)
|
177 (83.1%)
|
|
Corticosteroids
|
208
|
79 (37.9%)
|
85 (40.9%)
|
|
User of corticosteroids in the 2-year period
|
208
| |
93 (44.7%)
|
|
Antiresorptive osteoporosis treatment
|
209
|
47 (22.5%)
|
68 (32.5%)
|
|
Ever user of antiresorptive osteoporosis treatment
|
209
| |
92 (44.0%)
|
|
Calcium and/or vitamin D
|
210
|
113 (53.8%)
|
155 (73.8%)
|
